Meloxistad

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloxistad

Property Description
Active ingredient Meloxicam (INN)
Form Tablets (Rx), oral suspension, injectable solution, suppositories
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of inflammation, pain, and stiffness
Origin Synthetic compound, Oxicam derivative

What Type of Drug is Meloxistad? (Classification and Origin)

Meloxistad is a pharmaceutical preparation whose active substance is Meloxicam, a synthetic compound that belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. This chemical is an oxicam derivative, typically available by prescription only. The drug is clinically recognized for functioning as a preferential inhibitor of the COX-2 enzyme, which is primarily responsible for generating inflammatory signals. This classification confirms the drug's core function in providing symptomatic relief from both pain and inflammation.

A key differentiating feature of Meloxicam is its longer half-life compared to many traditional NSAIDs, which supports its common use in once-daily dosing regimens for managing chronic conditions. The COX-2 preferential action is a specific mechanical attribute intended to focus on the inflammatory pathway.

Active Ingredient and Available Forms (Composition and Presentation)

The sole active ingredient in Meloxistad is Meloxicam, which is manufactured as a single-ingredient product. The medicine is presented in several high-level dosage forms, including solid forms for oral intake, such as tablets and capsules, and liquid preparations like an oral suspension and an injectable solution. The availability of these multiple forms—oral, parenteral (intramuscular), and rectal—offers flexibility in treatment and administration.

Beyond the active Meloxicam, the final preparations incorporate pharmaceutical excipients—such as binders, diluents, and solvents—required to create the stable, administrable solid or liquid product. Importantly, Meloxicam capsules are often not interchangeable with other oral formulations (like tablets or suspension) due to differences in systemic exposure.

General Purpose: Anti-Inflammatory and Analgesic Action

The general purpose of Meloxistad is to provide sustained symptomatic relief by leveraging its principal anti-inflammatory and analgesic effects. The drug works by interrupting the body’s production of prostaglandins, thereby acting against the core manifestation of inflammation and reducing associated pain and stiffness. As an NSAID, it functions to reduce pain, tenderness, and swelling. This confirms that Meloxistad's primary mission is the long-term management of discomfort through its ability to modulate the inflammatory response.

Regulatory References

  1. Meloxicam: MedlinePlus Drug Information - NIH

What side effects are possible with Meloxistad?

Possible Side Effects and Safety Information

Meloxistad, a nonsteroidal anti-inflammatory drug (NSAID), carries mandatory regulatory warnings regarding its potential for serious adverse events.

Serious and Clinically Significant Risks

Official documents highlight two critical, potentially fatal risks associated with this drug and the NSAID class:

  • Cardiovascular (CV) Thrombotic Events: The drug may increase the risk of serious CV thrombotic events, including myocardial infarction (MI) and stroke. This risk may occur early and increase with duration of use, and use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal (GI) Events: The drug increases the risk of serious GI adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events may occur without warning symptoms, particularly in older adults.

Other serious adverse reactions documented include hepatotoxicity, renal toxicity (e.g., acute renal failure, hyperkalemia), hypertension, heart failure and edema, and anaphylactic reactions.

Common Adverse Reactions

The most commonly reported adverse events (very common / common) involve the gastrointestinal system and include diarrhea, dyspepsia (indigestion), abdominal pain, and nausea. Other common effects include upper respiratory tract infections and influenza-like symptoms.

Population-Specific Safety Notes

Population Safety Consideration
Late Pregnancy Contraindicated from approximately 30 weeks gestation onward due to risk of premature closure of the fetal ductus arteriosus.
Older Adults Higher risk for serious GI adverse events. Monitoring for renal and cardiac function is often warranted.
Hypersensitivity Contraindicated for individuals with a history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.

Safety Monitoring and Restrictions

  • Patients are monitored for signs of hepatic injury, new-onset or worsening hypertension, and renal impairment.
  • The drug should be used at the lowest effective dose for the shortest possible duration to minimize the potential for serious CV and GI risks, as the risk may be dose- and exposure-related.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Meloxicam (Meloxistad) overdose outlines both the expected clinical manifestations and mandatory emergency actions.

Documented Overdose Presentations

Acute Meloxicam overdose may initially present with nausea, vomiting, epigastric pain, and abdominal pain. Central nervous system effects such as drowsiness and lethargy have also been documented. Regulatory documents confirm that high-dose exposure increases the risk of gastrointestinal bleeding.

Severe Outcomes and Required Actions

Overdose can lead to severe and potentially life-threatening outcomes, which require immediate medical intervention. These include acute renal failure, cardiovascular collapse, respiratory depression, hepatic dysfunction, and convulsions.

Due to the potential for these severe events, official regulatory guidance mandates that individuals seek immediate medical attention if overdose is suspected. This involves contacting emergency services or a poison control center immediately.

Management and Considerations

No specific antidote is known for acute Meloxicam toxicity; therefore, management is focused on symptomatic and supportive treatment. Procedures described in regulatory texts may include gastric lavage, activated charcoal, or the administration of Cholestyramine to accelerate drug elimination. Elderly patients and those with pre-existing conditions (e.g., renal impairment) are noted in labeling as being at a greater risk for serious complications following an overdose.

Therapeutic Uses of Meloxistad

What Meloxistad Treats: Main Uses and Benefits

Meloxistad is commonly used to provide symptomatic relief for conditions presenting with systemic or localized discomfort related to inflammatory and painful symptoms. Its primary therapeutic role is focused on chronic musculoskeletal disorders.


Therapeutic Scope and Conditions

This medication is applied across domains where additional symptomatic support is needed for chronic conditions. It is relevant for managing the signs and symptoms of Osteoarthritis (OA) and Rheumatoid Arthritis (RA) in adults, and Juvenile Idiopathic Arthritis (JIA) in children two years of age and older. It is considered relevant in conditions like Ankylosing Spondylitis. Meloxistad is relevant for managing symptoms that interfere with daily comfort, focusing on symptoms related to physical discomfort such as pain, tenderness, stiffness, and swelling in the joints.

It is often used during phases when symptoms become more noticeable, such as when short-term supportive relief is needed after minor orthopedic or dental procedures. This focus contributes to easing the overall symptom load, and **supports patients during episodes of heightened discomfort.


Quick Fact: Support for Joint Stiffness
Meloxistad is commonly used to help with the symptoms related to physical discomfort of stiffness in arthritic joints, particularly the morning stiffness.

Regulatory References

  1. DailyMed official labeling verified by the NIH

Eligibility and Restrictions for Use

Meloxistad (Meloxicam) eligibility is strictly defined by regulatory documents, which establish specific population criteria for use, restriction, or absolute prohibition.

Populations for Whom Use is Contraindicated

Use is strictly prohibited in patients with a known hypersensitivity to meloxicam or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including those with a history of aspirin-sensitive asthma. It is also contraindicated for managing peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with active peptic ulceration or severe heart failure.

Age-Related and Organ Function Eligibility

Meloxistad is not approved for use in children younger than 2 years of age (US labeling). For older adults (geriatric patients), careful monitoring is required due to the increased risk of gastrointestinal issues. Patients with non-dialyzed severe renal failure or severely impaired liver function must not use the medicine. However, patients on hemodialysis may use it under a maximum restricted dose.

Pregnancy and Lactation Status

Use is contraindicated during the third trimester of pregnancy (at or after 30 weeks gestation). Use between 20 and 30 weeks is restricted and must be limited to the lowest effective dose for the shortest duration. Due to a lack of safety data, use is generally not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Meloxistad (Meloxicam) describes specific interaction patterns that can alter drug exposure or increase pharmacodynamic risk.

Contraindicated and High-Risk Combinations

Specific co-administrations are formally contraindicated. The Meloxistad oral suspension is prohibited for use with Sodium Polystyrene Sulfonate (Kayexalate) due to the risk of intestinal necrosis. Co-administration is also contraindicated in patients with a history of allergic-type reactions to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Combining Meloxistad with other NSAIDs is generally not recommended due to an officially documented additive risk of serious gastrointestinal events.

Pharmacokinetic and Pharmacodynamic Effects

Meloxistad modifies the clearance of certain medicines, resulting in increased systemic exposure. Co-administration reduces the renal clearance of Lithium and Methotrexate, which raises their plasma concentrations and increases the risk of toxicity. The profile also notes pharmacodynamic interactions that increase the risk of bleeding when combined with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, Corticosteroids, or SSRIs/SNRIs. Additionally, co-administration with ACE Inhibitors or ARBs may diminish their intended antihypertensive effect.

Substances and Specific Cautions

  • Alcohol (Ethanol) is officially documented to increase the risk of gastrointestinal bleeding.
  • Food: Meloxistad tablets can be administered without regard to the timing of meals.
  • Population-Specific: The interaction with ACE Inhibitors/ARBs leading to a greater deterioration of renal function is specifically noted for elderly, volume-depleted, or renally impaired patients.

Mechanism of Action

How Meloxistad Works

The physiological action of Meloxistad is defined by its ability to preferentially interfere with enzyme-mediated inflammatory signaling pathways via its active ingredient, Meloxicam.


Molecular Mechanism: Preferential Inhibition of COX-2

Meloxicam functions as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which is responsible for synthesizing the potent inflammatory mediator Prostaglandin E2 (PGE2). This competitive blockade interrupts the Arachidonic Acid Cascade, blocking the initial molecular step in prostanoid synthesis. The mechanism is defined by its higher binding affinity for the inducible COX-2 enzyme compared to the constitutive COX-1 enzyme.


Cascading Effect on Physiological Responses

The molecular inhibition of COX-2 initiates a cascading physiological response that results in functional changes within two main systems. Firstly, the resulting reduction in local prostaglandin levels helps dampen excessive vasodilation and fluid accumulation, contributing to the reduction of tissue fluid accumulation. Secondly, the scarcity of PGE2 at the periphery decreases the sensitization of nociceptors (pain-sensing nerves), which results in the modulation of peripheral nociceptive signaling originating from the site of action. Furthermore, the mechanism acts centrally by suppressing PGE2 synthesis in the hypothalamus, influencing the body's thermoregulation.


Mechanistic Limitations and Specificity

The mechanism's specificity is functionally dependent on concentration. While classified as preferential, the inhibition of the protective COX-1 enzyme still occurs at higher concentrations, representing a functional limit on the selectivity profile. A further mechanistic characteristic is the relatively slower onset of the full anti-inflammatory effect compared to the initial analgesic effect, as this requires time for the inflammatory cascade to fully subside after the enzyme block is established.

Dosage and Administration Information

How to Use Meloxistad (Meloxicam) – Administration Guidelines

Meloxistad, a brand name for meloxicam, must be used exactly as prescribed, adhering strictly to the instructions outlined in the product labeling. This guidance is based on established administration standards for the drug.


Dosing and Administration

Administration Detail Guideline
Route of Administration Oral (tablet, capsule, or suspension) or Intravenous (IV) bolus injection.
Standard Dosing Schedule Taken once daily (qDay). Adult oral doses are typically 7.5 mg or 15 mg. The maximum daily oral dose is 15 mg.
Timing Relative to Meals May be taken with or without food.
Preparation Oral suspension must be shaken gently before measuring the dose.

Procedural and Population-Specific Rules

Special Conditions:

  • Intravenous (IV) use requires the 30 mg dose to be administered as an IV bolus injection over 15 seconds. Patients should be well-hydrated prior to IV administration.
  • Pediatric Dosing: For children aged two years and older with Juvenile Idiopathic Arthritis, the dose is weight-based (0.125 mg/kg) and must not exceed 7.5 mg daily.
  • Renal Impairment: For patients undergoing hemodialysis, the maximum oral dose is significantly reduced, for example, not exceeding 7.5 mg/day to prevent accumulation.

Important: The lowest effective dose should be used for the shortest duration necessary. If a dose is missed, take the next dose at the regular scheduled time; do not double the dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Meloxistad

Evidence for Use in Osteoarthritis (OA) in Adults

Research for Meloxistad was conducted using short-term and intermediate-term Randomized Controlled Trials (RCTs) in adult patients with Osteoarthritis. These studies examined outcomes related to physical discomfort, such as pain intensity and joint stiffness, along with functional measures like the WOMAC physical function score. Findings describe the patterns of measured changes in patient-reported scores observed in the studies over the short study intervals (typically 4 to 12 weeks). The evidence is generally focused on short-term study intervals, and long-term effects are not fully established.


Evidence for Use in Rheumatoid Arthritis (RA) in Adults

Studies exploring Rheumatoid Arthritis also relied on RCTs and active-controlled designs. Research monitored standard disease activity criteria, including the ACR 20 response, and used counts of tender and swollen joints as outcomes reflecting daily functioning. The studies report how symptoms evolved in the observed populations during the trial periods. Research explored outcomes related to temporary physiological imbalance, but the evidence does not provide insight into whether the product alters the underlying structural progression of the disease.


Evidence in Special Populations and Acute Pain

Research for Juvenile Idiopathic Arthritis (JIA) in children (2 to 16 years of age) relies on a smaller evidence base, utilizing double-blind, active-controlled studies that measured the ACR pediatric 30% improvement criteria. Separately, research evaluated an intravenous (IV) formulation in acute settings, such as following surgery. The findings from these IV studies are specific to rapid, short-term pain intensity measurements and are not directly applicable to the oral forms.


Evidence Gaps, Limitations, and Areas of Uncertainty

Major limitations exist across the research landscape. Follow-up durations were limited in the high-quality comparative trials for chronic conditions. Data for certain groups remain insufficient, as the sample sizes were modest in the key pediatric studies. Furthermore, comparative evidence is often lacking for long-duration trials directly comparing Meloxistad against all other available nonsteroidal anti-inflammatory drugs (NSAIDs).

Key Studies & References

  1. Study Details | NCT00279747 | A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) | ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Meloxistad (FAQ)


Q: How long does it typically take for Meloxistad to start working for joint pain?

A: Clinical studies suggest that some initial pain relief may be observed within the first day of treatment. Official information notes that the drug reaches its highest concentration in the blood within a few hours of administration. However, achieving the full anti-inflammatory effect may require several days of consistent therapy to become noticeable.

Q: Is it necessary to take Meloxistad with food?

A: According to official regulatory instructions, Meloxistad tablets can be taken either with or without food. Studies show that while taking it with a meal can impact the peak concentration in the blood, it does not significantly change the total amount of drug absorbed. Patients should follow the specific instructions provided by their healthcare professional.

Q: How long does Meloxistad stay in your system after the last pill?

A: The active ingredient in Meloxistad has a relatively long elimination half-life, which generally ranges from 15 to 20 hours. This is the approximate time required for the body to clear half of the drug. The drug is primarily metabolized to inactive substances, which are then cleared from the body through both urine and feces.

Q: What is the longest period of time people typically take Meloxistad for?

A: Regulatory guidance emphasizes that the lowest effective dose should be used for the shortest possible duration consistent with the patient’s treatment goals. This precaution is intended to minimize the potential risk of serious side effects that may increase with prolonged use. The precise duration of use is determined by the healthcare professional as part of an individualized treatment plan.

Q: What should I do if the pain doesn't improve after a few days on Meloxistad?

A: Official dosing guidelines indicate that a patient's response to the initial therapy is observed before any dose adjustment is made. If symptoms do not improve after a few days, such a situation would require consultation with a healthcare professional for re-evaluation or dose adjustment, as noted in the prescribing information.

Q: Why is the maximum recommended usage duration often short for this drug?

A: The short duration of use is recommended to reduce the risk of serious side effects associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) class. This is primarily to minimize the potential for cardiovascular events, such as heart attack and stroke, and gastrointestinal issues, like bleeding and ulceration, which may increase with the duration of treatment.

Q: Can Meloxistad be used for general back muscle aches?

A: Meloxistad is officially indicated and approved for treating the signs and symptoms of specific chronic inflammatory conditions, such as different forms of arthritis. The official labeling does not include indications for the relief of general or simple acute musculoskeletal pain like common back muscle aches.

Q: Does Meloxistad make you feel sleepy or drowsy?

A: Official product information for Meloxistad does not typically list drowsiness or excessive sleepiness among the most common adverse effects. However, side effects that may affect the central nervous system, such as dizziness, have been reported in clinical trials.

Q: Can Meloxistad cause high blood pressure in some individuals?

A: Yes, official safety warnings state that drugs in the NSAID class, including Meloxistad, can lead to the new onset or worsening of pre-existing high blood pressure. Due to this potential risk, monitoring of blood pressure is frequently warranted during treatment with this drug class.

Q: Is it normal to feel a bit dizzy after starting Meloxistad?

A: Dizziness is a possible side effect of Meloxistad that has been documented in clinical trial data. While documented, patients who experience dizziness should be cautious with activities that require alertness, as this effect is possible when starting the medication.

Q: Is there a risk of addiction or dependence with Meloxistad?

A: Meloxistad is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not designated as a controlled substance, and official regulatory documents do not include warnings regarding addiction or dependence.

Q: Can I drive or operate machinery after taking Meloxistad?

A: Because side effects such as dizziness are possible, patients should exercise caution regarding activities that require alertness, such as driving or operating machinery. This is generally necessary until the individual understands the medication’s effects.

Q: How is Meloxistad eliminated from the body?

A: The active ingredient, meloxicam, is almost completely broken down into inactive substances by the body's metabolism. These inactive breakdown products are then eliminated from the body in roughly equal amounts through both the urine and the feces.

Q: Can Meloxistad be used to treat a simple headache or fever?

A: Meloxistad is officially indicated for the relief of signs and symptoms related to specific long-term inflammatory conditions, such as osteoarthritis and rheumatoid arthritis. Its approved uses do not include the treatment of general or simple conditions like minor headaches or fever.

Q: Are there different strengths or formulations of Meloxistad available?

A: Yes, the active ingredient (meloxicam) is available in several forms for oral administration, including tablets, oral suspension, and capsules, in various dose strengths. It is important to note that the established maximum daily oral dose for meloxicam remains consistent across different formulations.

Q: What's the research status on Meloxistad for non-arthritic inflammatory conditions?

A: The drug’s official regulatory indications are strictly limited to the management of specific arthritic conditions. Its effectiveness and safety for inflammatory conditions outside of osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis have not been established in the currently approved regulatory labeling.

Q: Is it okay to take antacids while on Meloxistad?

A: Regulatory studies found no clinically significant interaction when Meloxistad was administered concurrently with antacids. However, any changes to a patient’s medication regimen, including the use of over-the-counter products, should be discussed with a healthcare professional.

Q: Can Meloxistad affect sleep patterns?

A: The official product information does not list specific sleep disturbances among the most common adverse reactions. However, because the drug can have central nervous system-related side effects, patients are generally encouraged to observe their response to the medication.

Q: Is it common for people to get edema or swelling while taking Meloxistad?

A: Edema (swelling) is a documented adverse event, though it is not listed among the most frequently reported side effects. It is also important to note that the official warnings for this drug class list heart failure and edema as a serious potential risk.

How should Meloxistad be stored and disposed of?

Storage and Handling Requirements

Meloxistad (Meloxicam) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from both moisture and light to ensure stability. Official labeling dictates that liquid formulations, such as oral suspensions, must be strictly kept from freezing.

Child-Safety and Disposal

As a mandatory safety precaution, Meloxistad must be stored out of the sight and reach of children.

For disposal, unused or expired product should not be thrown in household trash or flushed down the toilet unless explicitly instructed by a health authority. Unused product must be discarded in accordance with local requirements, which usually involves utilizing an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloxistad found in:

A-Z Index: